Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2017

View Archived Issues

Acorda Therapeutics decides to discontinue tozadenant development program

Desidustat approved as INN for Zydus Cadila's ZYAN-1

Lu-AA-41178 demonstrates efficacy in animal models of epilepsy, schizophrenia and depression

PledPharma and Solasia to develop and commercialize PledOxin Asia

Aurigene moves oral VISTA/VSIG8 antagonist AUPM-493 towards clinical development

Starpharma gives update on rolling NDA for VivaGel BV

FDA accepts, grants priority review to lofexidine NDA

gamma-Secretase modulator ACD-678 has properties supporting development for Alzheimer's disease

FDA approves Kaleo's Auvi-Q epinephrine autoinjector

BMS-986141 prevents arterial thrombosis in monkeys

Ardelyx discontinues development of RDX-7675

Catalyst Pharmaceuticals begins phase II proof-of-concept study of Firdapse

Phase III VITALITY-ALS study of tirasemtiv in ALS does not meet primary endpoint

Kaken Pharmaceutical evaluates novel prostanoid EP4 receptor antagonist for rheumatoid arthritis

EMA launches improved version of EudraVigilance system for safety monitoring

FDA gives orphan drug status to TRM-201 for hemophilic arthropathy

Immunovaccine and Leidos to develop malaria vaccine candidates

Janssen submits applications in U.S. and E.U. to expand approval of Darzalex

Sumitomo Dainippon Pharma and Angelini enter European license and distribution agreement for Latuda

Columbia University patents anti-RAGE antibodies

OriMabs presents new anti-PSMA antibodies for prostate cancer

Spingotec Therapeutics divulges DPP3 inhibitors

Dosing begins in registrational trial of derazantinib

Jiangsu MicroMedMark Biotech patents KRAS-targeting siRNAs for cancer

Menlo Therapeutics begins enrollment in PSORIXA study of serlopitant

Zebra Biologics and Scripps Research Institute disclose Trk-B agonist antibodies

Immunoproteasome inhibitor KZR-616 shows promise in phase I study

BARDA exercises option under Imvamune smallpox vaccine contract

FDA approves Juluca, the first two-drug regimen for treatment of HIV-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...